Rega Institute for Medical Research

Global Virus Network’s Top Virologists Partner with Monaco to Advance Pandemic Preparedness Across EU Countries

Retrieved on: 
Friday, October 20, 2023
Global Virus Network, Big data, Artificial intelligence, Disease, Risk, Partnership, Public, AI, Citizen science, Hospital, Infection, Swiss Federal Institute of Technology, Medical research, SARS-CoV-2, Vaccine, HIV, CSM, University, United States National Library of Medicine, WHO, Duke–NUS Medical School, Data collection, Research, Prince, Politics, COVID, World Health Organization, Travel, Privacy, Rega Institute for Medical Research, European Bioinformatics Institute, Climate change, National library, Swiss Federal Institute of Aquatic Science and Technology, GVN, Virus, Genomics, Casino, Pharmaceutical industry, Medical device

Prince Albert II of Monaco, among other dignitaries including from the World Health Organization (WHO) and the GVN.

Key Points: 
  • Prince Albert II of Monaco, among other dignitaries including from the World Health Organization (WHO) and the GVN.
  • Prince Albert II of Monaco said, “I am delighted to support and attend this symposium to improve pandemic preparedness here in Monaco and abroad.
  • We have a duty to remain vigilant, strengthen global governance, and strengthen infrastructure and healthcare systems.
  • Studies showed that phone apps tracking COVID cases and notifying those with exposure, significantly impacted hospitalization and death rates.

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

Retrieved on: 
Wednesday, February 8, 2023
MSD, Pathogen, MBA, CHB, National Institute of Allergy and Infectious Diseases, Infection, COVID-19, Plasma protein binding, Metropolitan, Rega Institute for Medical Research, GLP, Sirna, Therapy, NASH, Jacob Aligo, NIH, Leuven Centre for Global Governance Studies, NIAID, Patient, Fatty liver disease, SAN, Merck, Merck & Co., Degenerative disease, SAD, Liver disease, Workforce, Drug design, Doctor of Philosophy, Discovery, Research, KU Leuven, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck & Co. (MSD outside the U.S. and Canada). Additionally, the Company plans to complete the ≤48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations.

Key Points: 
  • As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024.
  • “I would like to express my sincere gratitude to the employees who are being affected by this reprioritization.
  • ALG-055009 – the Company’s THR-β agonist in development for NASH is expected to complete an ongoing Phase 1 study in H1 2023.
  • Aligos plans to continue to support its collaboration agreements, including the agreement with Merck & Co. to develop oligonucleotide candidates to address NASH.

Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting

Retrieved on: 
Thursday, December 8, 2022
Hepatitis, Liver disease, SAN, CD3, Security (finance), Drug design, NASH, Treatment, Doctor of Philosophy, Degenerative disease, CHB, Human, Viral hepatitis, Rega Institute for Medical Research, Drug development, Serum, KU Leuven, MBA, Therapy, Severe acute respiratory syndrome coronavirus 2, Fatty liver disease, Institute of Liver and Biliary Sciences, COVID-19, Pharmaceutical industry, Vaccine, Biology, Jacob Aligo

In human airway epithelium cell cultures, ALG-097558 demonstrated efficient inhibition of viral replication with EC99.9 values of 5.3 and 54 nM, respectively, with or without 40% human serum.

Key Points: 
  • In human airway epithelium cell cultures, ALG-097558 demonstrated efficient inhibition of viral replication with EC99.9 values of 5.3 and 54 nM, respectively, with or without 40% human serum.
  • In the SARS-CoV-2 hamster infection model, efficient reduction of viral replication was demonstrated using a therapeutic dosing regimen with low oral doses of ALG-097558.
  • Finally, the ALG-097558 ADME profile predicts a 370-600 mg twice-daily dosing regimen in humans without the need for ritonavir boosting.
  • Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, CEO, GLOBE, R, Investment, European Association for the Study of the Liver, Board, Security (finance), Center, Patient, KU Leuven, CTA, Protease, Drug design, CAM, G&A, Fatty liver disease, Infection, HBsAg, Degenerative disease, Terminology, ASO, CHB, Institute of Liver and Biliary Sciences, EASL, Congress, SAN, Safety, Doctor of Philosophy, Nasdaq, Pharmacokinetics, Medical research, HBeAg, PF-07321332, Forward-looking statement, EC50, NASH, Therapy, COVID-19, Cell, Program, Drug development, Â, Severe acute respiratory syndrome coronavirus 2, Rega Institute for Medical Research, Association, Sirna, Liver disease, Viral hepatitis, Hepatitis, Research, MBA, CD3, Private Securities Litigation Reform Act, Pharmaceutical industry, Vaccine, Jacob Aligo, Liver

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today reported recent business progress and financial results for the second quarter June 30, 2022.
  • In the second quarter, we continued to make strong progress in advancing our drug candidates and discovery programs, said Lawrence Blatt, PhD, MBA, CEO and Chairman of the Board at Aligos.
  • ALG-000184 (CAM-2): Enrollment of HBeAg positive subjects in 28-day and 12-week cohorts evaluating various dose levels is ongoing.
  • We plan to share data from HBeAg positive cohorts at a scientific conference in Q4 2022.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Retrieved on: 
Wednesday, September 1, 2021
UCB, Rega, ACE2, Euronext, Degenerative disease, Twitter, Rega Institute for Medical Research, Ghent University, Severe acute respiratory syndrome coronavirus 2, Viral load, Immune system, Innovation, KU Leuven, Disease, Central nervous system, Antibody, Alpha, Clinical trial, Infection, VIB, VHH, Radio, Safety, Patient, Solution, Gamma, COVID-19, Professor, Vaccine, Pharmaceutical industry

The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.

Key Points: 
  • The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.
  • The study will sequentially evaluate three different doses of intravenously administered XVR011 with the primary endpoint of proportion of patients with adverse events.
  • Secondary endpoints include viral load, need for oxygen supplementation, clinical score (8-point ordinal scale) and other measures of clinical activity.
  • ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapiesproviding broad protection against viral infections, including coronaviruses.

ExeVir Announces First Patient Enrolled in Phase 1b/2 Clinical Study evaluating XVR011 as antiviral treatment of patients hospitalised for COVID-19

Retrieved on: 
Wednesday, September 1, 2021
UCB, Rega, ACE2, Euronext, Degenerative disease, Twitter, Rega Institute for Medical Research, Ghent University, Severe acute respiratory syndrome coronavirus 2, Viral load, Immune system, Innovation, KU Leuven, Disease, Central nervous system, Antibody, Alpha, Clinical trial, Infection, VIB, VHH, Radio, Safety, Patient, Solution, Gamma, COVID-19, Professor, Vaccine, Pharmaceutical industry

The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.

Key Points: 
  • The Phase 1b study will enrolup to 27 patients with mild to moderate symptoms caused by the SARS-CoV-2 coronavirus.
  • The study will sequentially evaluate three different doses of intravenously administered XVR011 with the primary endpoint of proportion of patients with adverse events.
  • Secondary endpoints include viral load, need for oxygen supplementation, clinical score (8-point ordinal scale) and other measures of clinical activity.
  • ExeVir Bio is a clinical stage company harnessing its VHH technology platform to generate robust antiviral therapiesproviding broad protection against viral infections, including coronaviruses.

Aligos Therapeutics and KU Leuven Announce Collaboration for the Development of a Therapeutic Candidate Targeting Coronavirus

Retrieved on: 
Wednesday, July 1, 2020
Viruses, Leuven, Animal virology, Coronaviridae, Zoonoses, Coronavirus, Rega Institute for Medical Research, Severe acute respiratory syndrome-related coronavirus, Antiviral drug, KU Leuven, Severe acute respiratory syndrome

In this collaboration, Johan Neyts research group and CD3 will join forces with Aligos, whose team has extensive experience in antiviral drug discovery, development and viral protease inhibitor chemistry.

Key Points: 
  • In this collaboration, Johan Neyts research group and CD3 will join forces with Aligos, whose team has extensive experience in antiviral drug discovery, development and viral protease inhibitor chemistry.
  • Their combined objective is to develop a therapeutic candidate designed to target the SARS-CoV-2 infection as well as other coronavirus infections.
  • CD3 was set up in 2006 by KU Leuven Research & Development and the European Investment Fund (EIF) and launched a 60 million euro fund in 2016.
  • The Rega Institute for Medical Research is a biomedical research institute of KU Leuven that comprises the Laboratory of Virology and Chemotherapy, which specializes particularly in antiviral research.